Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges - Seite 2
About CollegeBuys
CollegeBuys is the Foundation’s systemwide procurement vehicle that leverages the buying power of California’s 116 community colleges to offer discounts of up to 85
percent on a wide range of educational products—from industry-leading software and technology to high quality office and classroom furniture. For more information, visit www.collegebuys.org.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients
diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has
metastasized to the central nervous system. Biocept’s patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during
this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.
Lesen Sie auch
Forward-Looking Statements
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations
and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate,"
"believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly
historical, including without limitation statements regarding our ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety
of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of
such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be
accessed over the Internet at the SEC's website located at www.sec.gov.